TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39570708

Group type: EXPERIMENTAL
Intervention: 177Lu-Dotatate treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Somatostatin analogues (lanreotide [Somatuline] and octreotide [Sandostatin])
Number of subjects: 0

Group type: COMPARATOR
Intervention: Targeted therapy (everolimus [Afinitor] and sunitinib [Sutent])
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 39570749

Group type: EXPERIMENTAL
Intervention: Selexipag starting doses of 100, 150, and 200 μg twice daily for body weight groups ≥9 to <25 kg, ≥25 to <50 kg, and ≥50 kg respectively; maximum allowed doses of 800, 1200, and 1600 μg twice daily.
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Selexipag dose regimen for pediatric PAH patients.
Number of subjects: 63
Study: 39570957

Group type: EXPERIMENTAL
Intervention: ADaptivE PrenaTal (ADEPT) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NMM study (adaptive components of the intervention)
Number of subjects: 0
Study: 39570992

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens (oCEE) - Premarin, 0.45 mg/d
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (tE2) - Climara, 50 μg/d
Number of subjects: 299

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study: 39571113

Group type: EXPERIMENTAL
Intervention: Automated heart-health assessment (AH-HA) tool
Number of subjects: 645

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 645
Study: 39571155

Group type: EXPERIMENTAL
Intervention: PANDAH app
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PANDAH app for 6 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Care as usual or waiting list
Number of subjects: 100
Study: 39571150

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Lifestyle Intervention (MHB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Health Enhancement Program (HEP)
Number of subjects: 50
Study: 39571171

Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Number of subjects: 30

Group type: COMPARATOR
Intervention: CAR-T
Number of subjects: 30
Study: 39571342

Group type: EXPERIMENTAL
Intervention: Beetroot juice (200 mL daily, ∼600 mg nitrate)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (∼60 mg nitrate)
Number of subjects: 31
Study: 39571543

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (GHT)
Number of subjects: 207
Study: 39571597

Group type: EXPERIMENTAL
Intervention: High certainty of survival benefit
Number of subjects: 870

Group type: EXPERIMENTAL
Intervention: 1-year delay in FDA approval time
Number of subjects: 870

Group type: EXPERIMENTAL
Intervention: Very low certainty of survival benefit
Number of subjects: 870

Group type: EXPERIMENTAL
Intervention: Effect on surrogate endpoint
Number of subjects: 870
Study: 39571596

Group type: EXPERIMENTAL
Intervention: Short-course hypofractionated proton beam therapy
Number of subjects: 39
Study: 39571666

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Non-CEA carotids
Number of subjects: 205
Study: 39571744

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (AboBoNT-A) injections
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (AboBoNT-A) injections with guidance technique
Number of subjects: 384
Study: 39572166

Group type: EXPERIMENTAL
Intervention: Peripheral nerve stimulation and conventional medical management
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional medical management alone
Number of subjects: 36
Study: 39572264

Group type: EXPERIMENTAL
Intervention: CD25+FoxP3+ cell rate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CK+CD86+ cell rate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CD8+CD38+ MFI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CD8β infiltration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CK+HLAabc+ cell rate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CD8+CD28+ MFI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low CD8+CD38+ MFI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low CD8+CD28+ MFI
Number of subjects: 0
Study: 39572271

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% intraperitoneally during and after surgery
Number of subjects: 225

Group type: COMPARATOR
Intervention: Saline 0.9% (placebo) intraperitoneally during and after surgery
Number of subjects: 225
Study: 39572389

Group type: EXPERIMENTAL
Intervention: Combined CRMRF and PNF treatment
Number of subjects: 62

Group type: COMPARATOR
Intervention: PNF alone
Number of subjects: 62
Study: 39572395

Group type: EXPERIMENTAL
Intervention: Ibrutinib (560 mg once daily) in combination with bendamustine and rituximab (IBR) for six 28-day cycles
Number of subjects: 56
Study: 39572487

Group type: EXPERIMENTAL
Intervention: Family Check-Up® (FCU®)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Community comparison arm
Number of subjects: 206
Study: 39572525

Group type: EXPERIMENTAL
Intervention: Neoadjuvant oncolytic virus orienX010 and anti-PD-1 toripalimab for 12 weeks before surgery
Number of subjects: 30
Study: 39572681

Group type: COMPARATOR
Intervention: Healthy controls (n=25)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Periodontitis patients (n=25)
Number of subjects: 50
Study: 39572739

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) group, 250 µg injected into the silicone oil after surgery and at weeks 3 and 6 postoperatively.
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 74
Study: 39572763

Group type: EXPERIMENTAL
Intervention: Bariatric Surgery (SG or RYGB)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Bariatric Surgery (SG)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Bariatric Surgery (RYGB)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Dietary Restriction (Control)
Number of subjects: 54
Study: 39572762

Group type: EXPERIMENTAL
Intervention: Adaptive Universal Principles for Real-world Observational Studies (AUPROS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AUPROS
Number of subjects: 0
Study: 39572897

Group type: EXPERIMENTAL
Intervention: Tele-supervision group (TG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Direct supervision group (DG)
Number of subjects: 40
Study: 39572979

Group type: EXPERIMENTAL
Intervention: Nivolumab 300 mg every 2 weeks and ipilimumab 1 mg/kg every 6 weeks until disease progression or unacceptable toxicity
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nivolumab 300 mg every 2 weeks and ipilimumab 1 mg/kg every 6 weeks
Number of subjects: 15
Study: 39574036

Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESP)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block (TPV)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (standard general anaesthesia without intervention)
Number of subjects: 105
Study: 39574082

Group type: EXPERIMENTAL
Intervention: Intervention (not specified in detail)
Number of subjects: 4153

Group type: EXPERIMENTAL
Intervention: Comorbid anxiety symptoms
Number of subjects: 4153

Group type: EXPERIMENTAL
Intervention: Loneliness
Number of subjects: 4153

Group type: EXPERIMENTAL
Intervention: Need for informal care
Number of subjects: 4153

Group type: EXPERIMENTAL
Intervention: Lower cognitive capacity
Number of subjects: 4153

Group type: EXPERIMENTAL
Intervention: Absence of chronic pain
Number of subjects: 4153

Group type: EXPERIMENTAL
Intervention: Moderate-to-severe depressive symptoms
Number of subjects: 4153
Study: 39574099

Group type: EXPERIMENTAL
Intervention: Daycare attendance
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Later birth order
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Sibship size, delivery methods, and breastfeeding duration
Number of subjects: 178
Study: 39574115

Group type: EXPERIMENTAL
Intervention: Genomic profiling using next generation sequencing with a pan-cancer comprehensive panel.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genomic profiling results discussed at multidisciplinary tumor boards.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients participating in clinical trials post-genomic profiling.
Number of subjects: 0
Study: 39574155

Group type: EXPERIMENTAL
Intervention: Elamipretide
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 39574158

Group type: EXPERIMENTAL
Intervention: Weekday lunchtime meals delivered by a local volunteer or driver who also provides socialization and wellness checks
Number of subjects: 2300

Group type: COMPARATOR
Intervention: Biweekly delivery of 10 frozen meals to participants' homes
Number of subjects: 2300
Study: 39574186

Group type: EXPERIMENTAL
Intervention: Prochlorperazine maleate (oral, three times daily for 24 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (oral, three times daily for 24 hours)
Number of subjects: 0
Study: 39574193

Group type: EXPERIMENTAL
Intervention: Structured multimodal lifestyle program (including diet, exercise, cognitive training, vascular/metabolic risk management, social stimulation, sleep/stress management) supported by the LETHE App.
Number of subjects: 156

Group type: COMPARATOR
Intervention: Self-guided program (regular health advice; simplified App with no personalized/interactive content).
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Structured multimodal lifestyle program.
Number of subjects: 156

Group type: COMPARATOR
Intervention: Self-guided program.
Number of subjects: 156
Study: 39574198

Group type: EXPERIMENTAL
Intervention: Orthogeriatric co-management
Number of subjects: 2071

Group type: COMPARATOR
Intervention: Usual orthopedic care (control)
Number of subjects: 2071
Study: 39574220

Group type: EXPERIMENTAL
Intervention: MBX 2109 (200, 400, 600, and 900 μg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MBX 2109
Number of subjects: 40
Study: 39574348

Group type: EXPERIMENTAL
Intervention: Brensocatib (single oral dose)
Number of subjects: 28
Study: 39574505

Group type: EXPERIMENTAL
Intervention: PTSD group
Number of subjects: 0

Group type: COMPARATOR
Intervention: HC group
Number of subjects: 0
Study: 39574508

Group type: EXPERIMENTAL
Intervention: IVIG 10% administered at various dosing regimens (0.4-2 g/kg once every 1-4 weeks)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: IVIG 10% with dose splitting over multiple days
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: IVIG 10% with dosing intervals more frequent than Q4W
Number of subjects: 44

Group type: COMPARATOR
Intervention: IVIG 10%
Number of subjects: 44
Study: 39574523

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (LCD)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Low-fat isoenergetic control diet
Number of subjects: 13
Study: 39574950

Group type: EXPERIMENTAL
Intervention: PGT-A
Number of subjects: 940

Group type: COMPARATOR
Intervention: IVF-ET
Number of subjects: 940
Study: 39575028

Group type: EXPERIMENTAL
Intervention: Neoadjuvant anti-PD-L1 (Durvalumab) and anti-CTLA-4 (Tremelimumab) for three cycles of four weeks/cycle along with external beam radiation for five weeks, followed by wide surgical resection and adjuvant Durvalumab monotherapy for four cycles.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Neoadjuvant anti-PD-L1 (Durvalumab) and anti-CTLA-4 (Tremelimumab) with radiation.
Number of subjects: 18
Study: 39575188

Group type: EXPERIMENTAL
Intervention: Fenofibrate 160 mg once daily along with 1 g of mesalamine three times daily
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo along with 1 g of mesalamine three times daily
Number of subjects: 70
Study: 39575565

Group type: EXPERIMENTAL
Intervention: EMB-09 (a novel Fc-silenced tetravalent PD-L1/OX40 bispecific antibody)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EMB-09
Number of subjects: 0
Study: 39575611

Group type: EXPERIMENTAL
Intervention: Clonidine therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine therapy
Number of subjects: 0
Study: 39575620

Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Active TENS (subset with higher-than-median baseline anxiety)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo TENS (subset with higher-than-median baseline anxiety)
Number of subjects: 135
Study: 39575727

Group type: EXPERIMENTAL
Intervention: Smoking THC-predominant cannabis (S-THC)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Vaporizing THC-predominant cannabis (V-THC)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Vaporizing cannabidiol-predominant cannabis (V-CBD)
Number of subjects: 22
Study: 39575728

Group type: EXPERIMENTAL
Intervention: Unconditional Cash Transfers (UCT) + Medium-Quantity Lipid-Based Nutrient Supplement (LNS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unconditional Cash Transfers (UCT) + Medium-Quantity Lipid-Based Nutrient Supplement (LNS) + Social and Behaviour Change Communication (SBCC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unconditional Cash Transfers (UCT)
Number of subjects: 0
Study: 39575760

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Moderate hyperglycemia
Number of subjects: 200

Group type: COMPARATOR
Intervention: Severe hyperglycemia
Number of subjects: 200

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 200
Study: 39575854

Group type: EXPERIMENTAL
Intervention: Plasma pTau217 ratio (pTau217R)
Number of subjects: 144
Study: 39575943

Group type: EXPERIMENTAL
Intervention: Suture fixation
Number of subjects: 88

Group type: COMPARATOR
Intervention: Tension band wiring (control)
Number of subjects: 88
Study: 39575944

Group type: EXPERIMENTAL
Intervention: nPAP therapy (BiPAP, APAP, CPAP, ASV)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: nPAP therapy
Number of subjects: 241
Study: 39576059

Group type: EXPERIMENTAL
Intervention: Single-port transoral robotic surgery (SP TORS) for tongue base resection (TBR)
Number of subjects: 25
Study: 39576120

Group type: EXPERIMENTAL
Intervention: BD Onclarity HPV assay
Number of subjects: 3129

Group type: COMPARATOR
Intervention: Screening HPV-DNA assay (Cobas 4800 or HC2)
Number of subjects: 3129

Group type: COMPARATOR
Intervention: Cytology, p16/ki67 and E6/E7 mRNA triage results
Number of subjects: 3129
Study: 39576191

Group type: EXPERIMENTAL
Intervention: Perampanel
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 39576286

Group type: EXPERIMENTAL
Intervention: RBCT (robot-assisted exoskeleton gait training)
Number of subjects: 14

Group type: COMPARATOR
Intervention: CT (conventional therapy)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: RBCT
Number of subjects: 14

Group type: COMPARATOR
Intervention: CT
Number of subjects: 14
Study: 39576432

Group type: EXPERIMENTAL
Intervention: Efanesoctocog alfa Q1W
Number of subjects: 0

Group type: COMPARATOR
Intervention: Emicizumab Q1W or every 2 weeks
Number of subjects: 0
Study: 39576433

Group type: EXPERIMENTAL
Intervention: Efanesoctocog alfa
Number of subjects: 0
Study: 39576637

Group type: EXPERIMENTAL
Intervention: Intervention clinics with nurse care management for OUD treatment
Number of subjects: 290071

Group type: COMPARATOR
Intervention: Usual care clinics
Number of subjects: 290071
Study: 39576675

Group type: EXPERIMENTAL
Intervention: SMS and/or email reminders
Number of subjects: 446

Group type: COMPARATOR
Intervention: Control group (no reminders)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Overall vaccination coverage
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Vaccination coverage before and after COVID-19 pandemic
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Age ≥65 years
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Previous influenza vaccination
Number of subjects: 446
Study: 39576683

Group type: EXPERIMENTAL
Intervention: App-based self-management intervention (AEGORA)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 122
Study: 39576761

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy plus stenting
Number of subjects: 417

Group type: COMPARATOR
Intervention: Mechanical thrombectomy alone
Number of subjects: 417
Study: 39576798

Group type: EXPERIMENTAL
Intervention: Combined intervention (intensive dietary education, food reformulation, environmental changes to facilitate salt reduction, and salt meter utilization)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Standard education only (control group)
Number of subjects: 219
Study: 39576946

Group type: EXPERIMENTAL
Intervention: Intermittent FOLFIRI plus PAN (arm A)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Continuous FOLFIRI plus PAN (arm B)
Number of subjects: 137
Study: 39576962

Group type: EXPERIMENTAL
Intervention: Itacitinib 200 mg daily from day -3 through +100 or +180, followed by a taper
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Itacitinib 200 mg daily
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Itacitinib combined with standard GvHD prophylaxis
Number of subjects: 42
Study: 39576965

Group type: EXPERIMENTAL
Intervention: Daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) induction
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance for MRD-negative patients (n=24, group A)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: ASCT for MRD-positive transplant-eligible patients (n=8, group B)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: KRd consolidation for MRD-positive transplant-ineligible patients (n=4, group C)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Overall study results
Number of subjects: 39
Study: 39576977

Group type: EXPERIMENTAL
Intervention: Length AI algorithm (LAI)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: User experience with LAI algorithm
Number of subjects: 215
Study: 39576986

Group type: EXPERIMENTAL
Intervention: Selective FES (Fesia Grasp)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Traditional FES (Globus Elite)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Virtual Rehab Hands (Leap Motion sensor)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 80
Study: 39576989

Group type: COMPARATOR
Intervention: Same-day surgery
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Staged surgery
Number of subjects: 439
Study: 39577033

Group type: EXPERIMENTAL
Intervention: Chemotherapy treatment
Number of subjects: 98
Study: 39577128

Group type: EXPERIMENTAL
Intervention: Telemedicine visits with a psychologist conducting cognitive and mental health screenings, providing tailored brief psychotherapy and education.
Number of subjects: 17
Study: 39577214

Group type: EXPERIMENTAL
Intervention: IV calcium chloride 90 mg (C90D)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: IV calcium chloride 180 mg (C180D)
Number of subjects: 217

Group type: COMPARATOR
Intervention: IV NaCl 0.9% placebo (PD)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: IV calcium pretreatment (both doses)
Number of subjects: 217
Study: 39577326

Group type: EXPERIMENTAL
Intervention: Khanya (peer-delivered behavioral intervention)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU)
Number of subjects: 61
Study: 39577511

Group type: EXPERIMENTAL
Intervention: Donor-derived cell-free DNA (dd-cfDNA) levels before each EMB
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: dd-cfDNA threshold of 0.10%
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Combination of dd-cfDNA and NTproBNP
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Cut-off point of 0.10% for dd-cfDNA and 1,000 UI/ml for NTproBNP
Number of subjects: 206
Study: 39577691

Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids (ω3) and vitamin D (VitD) supplementation
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: ω3+VitD group
Number of subjects: 88

Group type: COMPARATOR
Intervention: ω3 group
Number of subjects: 88

Group type: COMPARATOR
Intervention: VitD group
Number of subjects: 88
Study: 39577708

Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (300,000 IU bolus followed by 1400 IU daily for 150 days)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation
Number of subjects: 307
Study: 39577821

Group type: EXPERIMENTAL
Intervention: planning + knowledge condition
Number of subjects: 603

Group type: COMPARATOR
Intervention: knowledge condition
Number of subjects: 603
Study: 39577828

Group type: COMPARATOR
Intervention: Control (no prednisone)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Pred Low (5 mg/d, every other week × 6 months)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Pred High (20 mg prednisone taper, every other month × 3 months)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Pred PRN (20 mg prednisone taper × 3 courses maximum if sperm counts were declining or 0)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 75
Study: 39577867

Group type: EXPERIMENTAL
Intervention: Indication-based prescribing tool
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 24
Study: 39577920

Group type: EXPERIMENTAL
Intervention: Early-start group (100 mg acetylsalicylic acid starting on the third day after surgery until the 90th day)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Late-start group (100 mg acetylsalicylic acid starting on the 30th day after surgery until the 90th day)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Early-start group
Number of subjects: 269

Group type: COMPARATOR
Intervention: Late-start group
Number of subjects: 269
Study: 39577921

Group type: EXPERIMENTAL
Intervention: Intravenous glibenclamide (8·6 mg over 72 h)
Number of subjects: 431

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study: 39577975

Group type: EXPERIMENTAL
Intervention: Urine-Xpert Ultra
Number of subjects: 1731

Group type: COMPARATOR
Intervention: AlereLAM
Number of subjects: 1731

Group type: EXPERIMENTAL
Intervention: Combination of Sputum-Xpert Ultra with AlereLAM
Number of subjects: 1731

Group type: EXPERIMENTAL
Intervention: Combination of Sputum-Xpert Ultra with Urine-Xpert Ultra
Number of subjects: 1731

Group type: EXPERIMENTAL
Intervention: Combination of all three tests (Sputum-Xpert Ultra, AlereLAM, Urine-Xpert Ultra)
Number of subjects: 1731
Study: 39578022

Group type: EXPERIMENTAL
Intervention: Anifrolumab
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Mobile application for patient-reported outcomes
Number of subjects: 500